PH Care COVID Survey: An International Patient Survey on the Care for Pulmonary Hypertension Patients during the Early Phase of the COVID-19 Pandemic

Abstract

Background: During the COVID-19 pandemic, most of the health care systems suspended their non-urgent activities. This included the cancellation of consultations for patients with rare diseases, such as severe pulmonary hypertension (PH), resulting in potential medication shortage and loss of follow-up. Thus, the aim of the study was to evaluate PH patient health status evolution, access to health care and mental health experience during the early phase of the pandemic. Methods:We conducted an online patient survey, available in 16 languages, between 22/05/2020 and 28/06/2020. The survey included questions corresponding to demographic, COVID-19 and PH related information.Results: 1073 patients (or relatives, 27%) from 52 countries all over the world participated in the survey. Seventyseven percent (77%) of responders reported a diagnosis of pulmonary arterial hypertension and 15% of chronic thromboembolic PH. The COVID-19 related events were few: only 1% of all responders reported a diagnosis of COVID-19. However, 8% of patients reported health deterioration possibly related to PH, and 4% hospitalization for PH. Besides, 11% of the patients reported difficulties to access their PH expert centre, and 3% interruption of treatment due to shortage of medication. Anxiety or depression was reported by 67% of the participants. Conclusion:Although COVID-19 incidence in PH patients was low, PH related problems occurred frequently as the pandemic progressed, including difficulties to have access to specialized care. The importance of primary health care was emphasized. Further studies are needed to evaluate the long-term consequences of COVID-related PH care disruption.

Self-help cognitive behavioural therapy for anxiety in pulmonary hypertension: pilot randomised controlled trial

“…Nevertheless, it could also reflect the impact of the COVID-19 pandemic [29], as highlighted by ten participants who discussed the pandemic as a reason for their participation. While participants found the intervention was helpful in managing their anxiety during the pandemic, it is not known whether this was translated to COVID-19-related anxieties.…”

How does the COVID-19 pandemic impact medication adherence of patients with chronic disease?: A systematic review

“…In order to mitigate the negative effect that COVID-19 brought on medication supplements and medication adherence for the chronically ill, certain measurements are to be taken into consideration by the government, healthcare organizations, and medical institutions. It is reported in an international survey targeting pulmonary hypertension patients that during the COVID-19 crisis, people discontinuing medication in the middle-income countries is twice the number of that in high-income countries, 32 which suggests that international organizations could give more assistance to low and middle-income countries with medication storage, and these countries themselves should put more attention to medication shortage issues. Additionally, some medication administering equipment can be properly collected, sterilized, and reused, such as metered-dose inhalers.…”

Desafios de hipertensos no acesso à atenção primária durante a pandemia de COVID-19: uma revisão integrada

“…As informações sobre o impacto do COVID-19 em várias condições hipertensivas raras devem ser disponibilizadas aos pacientes e cuidadores, mantendo-se vigilantes para evitar a disseminação de informações erradas. Esses dados podem ser de interesse para um maior planejamento de estratégias e organização de centros de cuidado especializado em hipertensão para garantir a continuidade dos cuidados e comunicações adequadas com pacientes, cuidadores e profissionais de saúde, incluindo médicos da atenção primária (Godinas et al, 2021).…”